Hero

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

1

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

2

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

Bringing breakthrough pioneering therapies to patients with life-threatening diseases

3

Bringing breakthrough pioneering therapies to patients with life-threatening diseases

Directing a weaponized attack on cancer with the NKR-T cell immunotherapy

4

Directing a weaponized attack on cancer with the NKR-T cell immunotherapy

About Celyad

Making the impossible possible for the patient

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

More info about Celyad

Latest News

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Discover all news

Carousel

Social Feed

"Si vous vous dites que votre marché c'est la Wallonie, une chose est sûre, vous n'irez jamais au-delà. Il faut voi… https://t.co/45obYxTvHW

6 days ago

"Si vous vous dites que votre marché c'est la Wallonie, une chose est sûre, vous n'irez jamais au-delà. Il faut voi… https://t.co/45obYxTvHW

@CelyadSA EMMÈNE LES BIOTECHS WALLONNES SUR LE NASDAQ https://t.co/8HAWNykjtf via @redacTendances #Wallonie #Biotech #SuccessStory

6 days ago

@CelyadSA EMMÈNE LES BIOTECHS WALLONNES SUR LE NASDAQ https://t.co/8HAWNykjtf via @redacTendances #Wallonie #Biotech #SuccessStory

Celyad emmène les biotechs wallonnes sur le nasdaq

6 days ago

Celyad emmène les biotechs wallonnes sur le nasdaq

Let's talk about NK cell receptors for cancer treatment! https://t.co/rOoHBdzyQG #immunotherapy #solidtumors… https://t.co/bzyNoIRGxD

1 week ago

Let's talk about NK cell receptors for cancer treatment! https://t.co/rOoHBdzyQG #immunotherapy #solidtumors… https://t.co/bzyNoIRGxD

"Si vous vous dites que votre marché c'est la Wallonie, une chose est sûre, vous n'irez jamais au-delà. Il faut voi… https://t.co/45obYxTvHW

6 days ago

"Si vous vous dites que votre marché c'est la Wallonie, une chose est sûre, vous n'irez jamais au-delà. Il faut voi… https://t.co/45obYxTvHW

@CelyadSA EMMÈNE LES BIOTECHS WALLONNES SUR LE NASDAQ https://t.co/8HAWNykjtf via @redacTendances #Wallonie #Biotech #SuccessStory

6 days ago

@CelyadSA EMMÈNE LES BIOTECHS WALLONNES SUR LE NASDAQ https://t.co/8HAWNykjtf via @redacTendances #Wallonie #Biotech #SuccessStory

Let's talk about NK cell receptors for cancer treatment! https://t.co/rOoHBdzyQG #immunotherapy #solidtumors… https://t.co/bzyNoIRGxD

1 week ago

Let's talk about NK cell receptors for cancer treatment! https://t.co/rOoHBdzyQG #immunotherapy #solidtumors… https://t.co/bzyNoIRGxD

"This patent is key for the players that are developing in the US allogeneic CAR-T cell approaches" said @ChristianHomsy CEO of Celyad.

1 week ago

"This patent is key for the players that are developing in the US allogeneic CAR-T cell approaches" said @ChristianHomsy CEO of Celyad.

Celyad emmène les biotechs wallonnes sur le nasdaq

6 days ago

Celyad emmène les biotechs wallonnes sur le nasdaq

Let's talk about NK cell receptors for cancer treatment! http://bit.ly/2nqiPRi #immunotherapy #solidtumors #Celyad #IOSummitUK

1 week ago

Let's talk about NK cell receptors for cancer treatment! http://bit.ly/2nqiPRi #immunotherapy #solidtumors #Celyad #IOSummitUK

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells http://bit.ly/2mRk36j #patent #allogeneic

1 week ago

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells http://bit.ly/2mRk36j #patent #allogeneic

"What we develop at Celyad is closer to a drug paradigm than to a cell transplant paradigm. With the CAR-T NKR-2 approach, we aim at delivering a therapy that, just like a vaccine, leverages the power of the patient’s immune system to eradicate tumors and prevent cancer from coming back" . Christian Homsy, CEO of Celyad

1 week ago

"What we develop at Celyad is closer to a drug paradigm than to a cell transplant paradigm. With the CAR-T NKR-2 approach, we aim at delivering a therapy that, just like a vaccine, leverages the power of the patient’s immune system to eradicate tumors and prevent cancer from coming back" . Christian Homsy, CEO of Celyad